2020 was the year that ripped off the band-aids holding together gaps in the life science supply chain. The pandemic swiftly revealed long-standing vulnerabilities in GDP and quality management processes, forcing industry-wide action. To strengthen the resiliency of their operations and remain competitive in the “new normal” all manufacturers – from the pharma and MedTech giants to small and mid-sized life science organizations – must adapt.
